trending Market Intelligence /marketintelligence/en/news-insights/trending/7azk1FVcD2D6l84TQQtFLA2 content esgSubNav
In This List

Starpharma's VivaGel condom gets marketing approval in Japan

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Starpharma's VivaGel condom gets marketing approval in Japan

Starpharma Holdings Ltd. said the Japanese Pharmaceuticals and Medical Devices Agency granted it final approval to market its VivaGel condom.

The Australian company's commercial partner in Japan, Okamoto Industries Inc., plans to launch the product in the first half of 2019.

Starpharma will receive royalty payments under its license with Okamoto Industries, which holds the majority share of Japan's condom market, according to a news release.

The VivaGel condom is already approved for sale in Australia and Canada under the Lifestyles Dual Protect brand.

Recently, the U.S. Food and Drug Administration asked for confirmatory clinical data in order to approve the company's antibacterial gel VivaGel BV, a treatment for bacterial vaginosis, a common bacterial infection in women.